Fig. 1: Outcome for patients treated by venetoclax combination therapy. | Blood Cancer Journal

Fig. 1: Outcome for patients treated by venetoclax combination therapy.

From: Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis

Fig. 1: Outcome for patients treated by venetoclax combination therapy.The alternative text for this image may have been generated using AI.

a Median response duration for all patients who achieved CR/CRi and according to their adverse (red line) or intermediate (blue line) cytogenetic risk. b Overall survival for the entire patient cohort and according to their adverse (red line) or intermediate (blue line) cytogenetic risk. c Patients were categorized into those who achieved CR/CRi without relapse (group 1; n = 7) or with relapse at any time during the study (group 2; n = 9) and patients who only achieved partial remission (PR) or with a refractory disease (RD) (group 3; n = 3). The presence of study ID number, indicated mutations, complex karyotype, percentage of LSCs among the total blast population and best response are shown for each case.

Back to article page